InMed Pharmaceuticals (INM) Current Assets (2020 - 2026)

InMed Pharmaceuticals' Current Assets history runs 7 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• On a quarterly basis, Current Assets rose 7.46% year-over-year to $6.9 million in Q1 2026; TTM through Mar 2026 was $6.9 million, a 7.46% increase from a year earlier, with the FY2025 full-year figure at $12.9 million, up 48.08% from the prior year.
• Current Assets declined to $6.9 million in Q1 2026 per INM's latest filing, from $8.8 million in the prior quarter.
• Across five years, Current Assets topped out at $14.0 million in Q4 2022 and bottomed at $5.5 million in Q4 2024.
• The 5-year median for Current Assets is $9.6 million (2022), against an average of $9.7 million.
• Across the five-year window, Current Assets slumped 53.68% in 2024 and jumped 60.67% in 2025, its largest moves.
• Year by year, Current Assets stood at $14.0 million in 2022, then dropped by 15.75% to $11.8 million in 2023, then slumped by 53.68% to $5.5 million in 2024, then soared by 60.67% to $8.8 million in 2025, then slipped by 21.63% to $6.9 million in 2026.
• Per Business Quant, the three latest INM Current Assets figures stand at $6.9 million (Q1 2026), $8.8 million (Q4 2025), and $10.8 million (Q3 2025).